NCI Research Specialist/Clinician Scientist Award for Urologic Oncology Research

项目摘要 作为一名泌尿外科肿瘤学家，我的大多数同行都专注于尽可能多地进行手术 希望他们的努力能对个人层面的变化产生积极影响。在我的NCI期间 泌尿外科肿瘤联谊会，我被临床发现的力量所吸引 临床调查员。外科医生在该领域创造范式转变的研究路径有限 在手术室之外，因为工业界经常忽视我们面临的许多关键问题。 幸运的是，NIH合作组织的网络试验为临床科学家提供了一条途径 通过与志同道合的个人、患者权益倡导者、翻译人员进行互动来影响该领域 研究人员、统计学家和运营人员。通过早期参与SWOG，我一直在 在担任更大的角色之前，有机会参与并领导几项临床试验 翻译研究计划。这坚定了我作为一名临床科学家的热情，希望领导 治疗肾癌的新举措。我很幸运地承担了共同主席的职责 SWOG的肾脏小组委员会和NCI肾脏工作组。这些领导角色使我能够 留下下一代临床试验的印记。这也包括我的一个小肾脏 旨在减少过度治疗的大规模试验，这是通过临床试验计划开发的 肾脏工作组的大部分成员都参加了会议，并在今年被列为SWOG的优先事项 计划在今年晚些时候由顾问团指导委员会进行审查。尽管获得了学术和领导力 认可，我通过试验参与NCI临床研究，管理 努力，指导SWOG调查人员，制定协议，以及两年一次的旅行 会议上，加州大学洛杉矶分校对这些努力的机构支持有限。同样，NCI 赞助的试验给工作人员和这名调查员造成了经济负担，与 行业试验。参与很大程度上是因为我热衷于为患者提供 改善护理的机会。R50研究专家奖机制表彰 个人可以在推进临床科学方面发挥关键作用，并可以显著提高我的 工作。特别是，与该奖项相关的财政支持将进一步推动我的参与 在现有的NIH方案中，为方案开发提供时间，包括我们新的小肾脏 大众概念，提供前往SWOG和肾脏特别工作组会议的手段，并允许 SWOG和肾脏工作组领导层要求的指定保护时间。本奖项 会在我的学术生涯发展中发挥重要作用 临床生产的压力。我为这个机会感到兴奋，并感谢加州大学洛杉矶分校认可 我为这次提名所做的努力。

Project Summary As a urologic oncologist, most of my peers have focused on operating as much as possible with the hope their efforts could positively effect change on an individual level. During my NCI Urologic Oncology Fellowship, I was drawn to the power of clinical discovery working alongside clinical investigators. A surgeon has limited research paths to create paradigm shifts in the field beyond the operating room, as industry often ignores many of the critical questions facing us. Fortunately, the NIH Cooperative Group network trials provide an avenue for clinical scientists to impact the field by interacting with likeminded individuals, patient advocates, translational researchers, statisticians, and operational staff. By early engagement in SWOG, I have been afforded the opportunity to participate and lead several clinical trials before taking larger roles in translational research initiatives. This cemented my passion as a clinician scientist hoping to lead new initiatives in kidney cancer. I am fortunate to have assumed Co-Chair responsibilities within SWOG’s Renal Subcommittee and the NCI Renal Task Force. These leadership roles allow me to imprint the next generation of clinical trials. This also includes my involvement with a small renal mass trial aimed at reducing overtreatment, that was developed through a Clinical Trials Planning Meeting by much of the Renal Task Force and has been prioritized within SWOG this year with plans for GU Steering Committee review later this year. Despite receiving academic and leadership recognition, my engagement in NCI clinical research throughtrial participation, administrative efforts, mentorship of SWOG investigators, protocol development, and travel for bi-annual meetings, there is limited institutional support at UCLA for these endeavors. Similarly, the NCI sponsored trials have resulted in a financial burden to staff and this investigator, as compared to industry trials. Participation has largely been a result of my passion to provide patients an opportunity for improved care. The R50 Research Specialist Award mechanism recognizes the critical role that individuals can play to advance clinical science and can significantly advance my work. In particular, the financial support associated with this Award will further my engagement in available NIH protocols, provide time for protocol development including our new Small Renal Mass Concept, provide the means to travel to SWOG and Renal Task force meetings, and allow designated protected time that SWOG and Renal Task Force leadership requires. This Award would be instrumental in my academic career development during a time where the is increasing pressure to produce clinically. I am thrilled for this opportunity and appreciate UCLA recognizing my efforts with this nomination.